| |
| | United States Patent Application: 0040204486 |
 | | For example, in embodiments, anandamide or a structurally related lipid is administered in an amount sufficient to modulate vascular tone; in an amount sufficient to modulate inflammation; in an amount sufficient to modulate sensory nerve activity, in an amount sufficient to achieve analgesia, and/or in an amount sufficient to modulate organ function. |
 | | Alternatively, if the concentration of anandamide or a structurally related lipid in the tested individual is determined to be normal or average for the relevant population, yet symptoms of excessive vasodilation, inflammation, pain, organ dysfunction, or vasoconstriction are seen in the tested individual hyperactivity or inactivity (respectively) of at least one vanilloid receptor is indicated. |
 | | The anandamide or structurally related lipid can be present in the kit as the sole component of the kit, or it can be present as part of a composition, alone or in combination with other compounds, solutions, or devices necessary or desirable for use of the anandamide or structurally related lipid. |
| appft1.uspto.gov /netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=/netahtml/PTO/srchnum.html&r=1&f=G&l=50&s1="20040204486".PGNR.&OS=DN/20040204486&RS=DN/20040204486 (13082 words) |
|